BeiGene is a Chinese life sciences biotechnology company that focuses on discovering and developing oncology drugs.
BeiGene is a Chinese life sciences biotechnology company that focuses on discovering and developing oncology drugs that address unmet medical needs in cancers prevalent in China and the Asia-Pacific region.
Founded in 2010, BeiGene specialise in novel drug discovery in the areas of both small molecules and biologicals, translational research with an emphasis on biomarker identification and validation in patients and bioinformatics based on human tumor genotyping and expression profiling.
The company aims to create a robust platform in China to enable the identification of specific subsets of patient populations that will identify patients who are most likely to benefit from the use of specific drugs or treatments. BeiGene aim to form a link between treatment sensitivity and molecular targets in order to develop future drug candidates with greater efficacy and safety.
In 2013 German drug maker Merck Serono made its second global licensing, co-development and commercialization deal with BeiGene. The contract, for the BeiGene-290 drug, will expand a partnership to cover the Chinese company’s two most advanced, locally developed oncology treatments.